Michael Schmertzler, Director at PTC THERAPEUTICS, INC. (PTCT), sold 20,000 shares at $67.79 ($1.4M) on 2026-09-09, disclosed to the SEC on 2026-09-11.
Scheduled sale ($1.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $67.79 | 9,428 | $639K | 47.3% |
| 2 | $68.67 | 572 | $39K | 2.9% |
| 3 | $67.34 | 10,000 | $673K | 49.8% |
| Total | $67.59 avg | 20,000 | $1.4M | 100% |
| Filing → |
| PTCT | SELL | 2026-08-28 | $1.8M | — | Filing → |
| PTCT | SELL | 2026-08-21 | $1.8M | — | Filing → |
| PTCT | SELL | 2024-01-10 | $42K | — | Filing → |